NDAOPHTHALMICSUSPENSION/DROPS
Approved
Jun 1963
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
MAXITROL (neomycin sulfate, polymyxin b sulfate and dexamethasone) by Novartis is corticosteroid hormone receptor agonists [moa]. Approved for corticosteroid [epc]. First approved in 1963.
Drug data last refreshed 15h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MAXITROL is a fixed-dose ophthalmic suspension combining neomycin sulfate and polymyxin B sulfate (broad-spectrum antibiotics) with dexamethasone (a corticosteroid) for topical eye treatment. It works through corticosteroid hormone receptor agonism to reduce inflammation while the antibiotics provide antimicrobial coverage. The product is indicated for corticosteroid-responsive inflammatory ocular conditions with bacterial infection or risk thereof.
LOE Approaching
Declining
minimal — competitor CIPRODEX ($6M) generates 2x spending despite similar LOE status
Product team is likely small and focused on defending legacy market share against superior fixed-dose competitors as LOE approaches.
Mechanism of Action
Corticosteroid Hormone Receptor Agonists
Pharmacologic Class:
Corticosteroid
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on MAXITROL offers limited growth opportunity but deep expertise in ophthalmology and generic transition strategy. This is a defensive role suited to professionals managing mature products through LOE and optimizing profitability in face of generic competition.
Brand Manager (Legacy/Defensive)Market Access Manager
Worked on MAXITROL at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.